Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hare

Showing results (651-660 of 873) with videos related to

Pageof 88
Sort By:
JACC. Heart Failure|November 19, 2025
Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD TrialSunjay Kaushal, Joshua M Hare, William T Mahle, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|April 27, 2017
Allogeneic Human Mesenchymal Stem Cell Infusions for Aging FrailtySamuel Golpanian, Darcy L DiFede, Aisha Khan, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|October 5, 2017
Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical TrialBryon A Tompkins, Darcy L DiFede, Aisha Khan, et al.
Circulation Research|September 20, 2017
Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study)Victoria Florea, Angela C Rieger, Darcy L DiFede, et al.
Journal of the American College of Cardiology|November 19, 2016
Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM TrialJoshua M Hare, Darcy L DiFede, Angela C Rieger, et al.
The Journal of Clinical Investigation|October 12, 2011
FGF23 induces left ventricular hypertrophyChristian Faul, Ansel P Amaral, Behzad Oskouei, et al.
JAMA|November 20, 2013
Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trialAlan W Heldman, Darcy L DiFede, Joel E Fishman, et al.
JACC. Cardiooncology|January 6, 2021
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA TrialRoberto Bolli, Emerson C Perin, James T Willerson, et al.
European Journal of Heart Failure|April 3, 2021
A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trialRoberto Bolli, Raul D Mitrani, Joshua M Hare, et al.
Circulation|February 18, 2017
Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells)Emerson C Perin, Michael P Murphy, Keith L March, et al.
Pageof 88

Showing results (651-660 of 873) with videos related to

Sort By:
Pageof 88
JACC. Heart Failure|November 19, 2025
Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD TrialSunjay Kaushal, Joshua M Hare, William T Mahle, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|April 27, 2017
Allogeneic Human Mesenchymal Stem Cell Infusions for Aging FrailtySamuel Golpanian, Darcy L DiFede, Aisha Khan, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|October 5, 2017
Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical TrialBryon A Tompkins, Darcy L DiFede, Aisha Khan, et al.
Circulation Research|September 20, 2017
Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study)Victoria Florea, Angela C Rieger, Darcy L DiFede, et al.
Journal of the American College of Cardiology|November 19, 2016
Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM TrialJoshua M Hare, Darcy L DiFede, Angela C Rieger, et al.
The Journal of Clinical Investigation|October 12, 2011
FGF23 induces left ventricular hypertrophyChristian Faul, Ansel P Amaral, Behzad Oskouei, et al.
JAMA|November 20, 2013
Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trialAlan W Heldman, Darcy L DiFede, Joel E Fishman, et al.
JACC. Cardiooncology|January 6, 2021
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA TrialRoberto Bolli, Emerson C Perin, James T Willerson, et al.
European Journal of Heart Failure|April 3, 2021
A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trialRoberto Bolli, Raul D Mitrani, Joshua M Hare, et al.
Circulation|February 18, 2017
Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells)Emerson C Perin, Michael P Murphy, Keith L March, et al.
Pageof 88